Study of VX-770 on Desipramine

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to evaluate the effects of VX-770 on Desipramine

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Vertex Pharmaceuticals Incorporated
• Treatments: Desipramine; Ivacaftor

Criteria

Inclusion Criteria:

• Subjects must be male or female and between 18 and 55 years of age

• Subject must have a body mass index (BMI) from 18 to 30 kg/m2

• Subject must be judged to be in good health

Exclusion Criteria:

• History of any illness that, in the opinion of the investigator or the subject's general practitioner, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject

• Subjects who have human immunodeficiency virus, hepatitis C, or active hepatitis B

• Female subjects and male subjects with female partner(s) who are pregnant, nursing, or planning to become pregnant during the study or within 90 days of the last dose of study drug